This site uses cookies to provide a better browsing experience. More information can be found on our Privacy Policy page.

NodThera has changed its name to Rezera and announced a Phase 3 development program. Read Press Release

publications & posters

Check out our scientific presentations to learn more about our ongoing drug development programs.

NLRP3 Inhibitor, NT-0796 Reduces MASH in Preclinical Models

Thornton, et al., Obesity Week 2025 | Atlanta, Georgia

Profile of NT-0527, a brain penetrant NLRP3 Inflammasome inhibitor suitable as an in vivo tool compound for neuroinflammatory disorders

Harrison, et al., RSC Medicinal Chemistry

Anti-neuroinflammatory and anti-inflammatory effects of the NLRP3 inflammasome inhibitor NT-0796 in subjects with Parkinson’s disease

Clarke, et al., Movement Disorders

The NLRP3 inhibitor NT-0796 enhances and sustains GLP-1R agonist-mediated weight loss in a murine diet-induced obesity model

Thornton, et al., Obesity

Brain Penetrant NLRP3 Inhibitors: The Discovery of a Panacea?

Harrison, Journal of Medicinal Chemistry

The ester-containing prodrug NT-0796 enhances delivery of the NLRP3 inflammasome inhibitor NDT-19795 to monocytic cells expressing carboxylesterase-1

Doedens, et al., Biochemical Pharmacology

See Our Development Pipeline